98%
921
2 minutes
20
This study presents a novel crosstalk-free dual-mode biosensing platform based on a single cerium-incorporated metal-organic framework (UiO-66-NH(Ce)) for sensitive detection of α-glucosidase activity and inhibitor screening. Unlike traditional dual-mode systems affected by signal interference, this monolithic MOF platform intrinsically produces orthogonal colorimetric and fluorescent responses. Upon α-glucosidase-mediated generation of hydroquinone, simultaneous signal transduction occurs through independent pathways: colorimetric attenuation via suppression of the oxidase-like catalytic process, and fluorescence recovery due to ligand-to-metal charge transfer modulation. Rigorously optimized for clinical application, the platform achieves ultra-low detection limits of 0.0166 U/L in colorimetric mode and 0.0094 U/L in fluorescent mode, surpassing existing methods. The platform demonstrates selectivity against potential interferents and successfully quantifies α-glucosidase in human serum with satisfactory recovery rates. Furthermore, the system facilitates precise inhibitor screening with IC values of 8.13 μM for fluorescence-based detection and 10.06 μM for colorimetric detection of acarbose. By integrating self-validating detection and drug evaluation within a single-material architecture, this work establishes a paradigm for designing robust MOF-based biosensors equipped with built-in cross-validation capabilities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.talanta.2025.128693 | DOI Listing |
Mol Divers
September 2025
Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.
Cyclin-dependent kinase 20 (CDK20), also known as cell cycle-related kinase (CCRK), plays a pivotal role in hepatocellular carcinoma (HCC) progression by regulating β-catenin signaling and promoting uncontrolled proliferation. Despite its emerging significance, selective small-molecule inhibitors of CDK20 remain unexplored. In this study, a known CDK20 inhibitor, ISM042-2-048, was employed as a reference to retrieve structurally similar compounds from the PubChem database using an 85% similarity threshold.
View Article and Find Full Text PDFNed Tijdschr Geneeskd
September 2025
Amsterdam UMC, Nederlands Instituut voor Pigmentstoornissen (SNIP), Amsterdam.
Vitiligo is a chronic skin disease characterized by white patches caused by the destruction of melanocytes. The most well-known variant is non-segmental vitiligo, where patches are symmetrically distributed across the entire body, with alternating periods of stability and progression. The white patches arise due to an autoimmune reaction in which cytotoxic T-cells attack the melanocytes.
View Article and Find Full Text PDFUrologia
September 2025
UROGIV Research Group, School of Medicine, Universidad Del Valle, Cali, Colombia.
Background And Objective: Bladder cancer (BC) is the sixth most common cancer in the U.S., with risk factors such as smoking, older age, and male sex.
View Article and Find Full Text PDFAim Search for subclinical manifestations of cardiotoxicity in cancer patients at high and very high risk of cardiotoxicity and evaluation of the effectiveness of drug primary prevention during the antitumor treatment. Material and methods The study included 150 cancer patients with a high and very high Mayo Clinic (USA) Cardiotoxicity Risk Score. The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China.
Background: Lung cancer remains the leading cause of cancer-related mortality globally, primarily due to late-stage diagnosis, molecular heterogeneity, and therapy resistance. Key biomarkers such as EGFR, ALK, KRAS, and PD-1 have revolutionized precision oncology; however, comprehensive structural and clinical validation of these targets is crucial to enhance therapeutic efficacy.
Methods: Protein sequences for EGFR, ALK, KRAS, and PD-1 were retrieved from UniProt and modeled using SWISS-MODEL to generate high-confidence 3D structures.